{"prompt": "['CANOPY GROWTH', 'Protocol #710-4502', 'CORPORATION', 'ABBREVIATIONS AND DEFINITIONS OF TERMS', 'Abbreviation/Term Definition', 'AE', 'Adverse event', 'BMI', 'Body mass index', 'BPI-SF', 'Brief Pain Inventory-Short Form', 'CBD', 'Cannabidiol', 'CGI-I', 'Clinician Global Impression-Improvement', 'eCRF', 'Electronic case report form', 'ECS', 'Endocannabinoid system', 'eICF', 'Electronic informed consent form', 'EQ5D-5L', 'Euro Quality of Life (QoL)', 'GCP', 'Good Clinical Practice', 'GPVD', 'Global Pharmacovigilance Department', 'IASP', 'International Association for the Study of Pain', 'ICF', 'Informed consent form', 'ICH', 'International Council for Harmonization', 'IME', 'Important Medical Event List', 'MME', 'Milligram morphine equivalents', 'MSL', 'Medical science liaison', 'NRS', 'Numeric rating scale', 'PGI-C', 'Patient Global Impression of Change', 'SAE', 'Serious adverse event', 'SD', 'Standard deviation', 'ST', 'Spectrum Therapeutics', '25 November 2020', 'CONFIDENTIAL', 'Page 13 of 79']['CANOPY GROWTH', 'Protocol #710-4502', 'CORPORATION', '1.', 'BACKGROUND INFORMATION AND STUDY RATIONALE', '1.1', 'Background', 'Chronic pain, defined by the International Association of Pain (IASP) as pain persisting or recurring for', 'more than three months, refers to a complex and heterogeneous group of disorders that produce significant', 'disability and emotional distress. 1-5 Studies suggest that chronic pain affects at least 10% of the worldwide', 'population, with estimates approaching 20-25% in meregions6.', 'According to IASP27, chronic pain is the \"parent code\" for 7 other codes that compromise the most common', 'clinically relevant groups of chronic pain conditions (Top-level diagnosis): (1) chronic primary pain; (2)', 'chronic cancer-related pain; (3) chronic post-surgical or post-traumatic pain; (4) chronic neuropathic pain;', '(5) chronic secondary headache or orofacial pain; (6) chronic secondary visceral pain; and (7) chronic', 'secondary musculoskeletal pain. Within the primary pain syndrome, pain is conceived as a disease or health', 'condition, whereas in secondary pain syndromes, pain is regarded as a symptom.', 'Given the limited access to physical and psychological interventions for chronic pain7-9 and', 'the', 'variable', 'efficacy and tolerability of currently available medications10,11 there is a growing interest in the use of', 'cannabinoids (medical cannabis and cannabis-based medicines) for chronic pain management. The', 'legalization of cannabis in at least 14 countries and regulatory approval of cannabis extract preparations, as', 'well as the emergence of synthetic cannabinoids and analogs, is expected to herald an increase in the number', 'of individuals seeking cannabinoids as a means of pain relief. A recent European Pain Federation position', 'paper provided a series of recommendations surrounding cannabis-based medicines to this effect12', 'Cannabis has a long history of therapeutic use for pain and other indications. Research into the', 'pharmacology of cannabinoids and their mechanisms of action 13 has led to the identification of', 'an', 'endocannabinoid system (ECS) in humans, composed of endogenous cannabinoids, the proteins responsible', 'for their synthesis, release and degradation, their associated metabolites, and cannabinoid receptors14 Of', \"more than 120 cannabis-derived phytocannabinoids, the majority of cannabis' effects are attributed to two\", 'compounds: delta-9-tetrahydrocannabinol (THC), the main psychoactive cannabinoid in cannabis, and', 'cannabidiol (CBD), a non-euphoric cannabinoid that has been investigated in pre-clinical studies for effects', 'on anxiety, cognition, inflammation, and pain 15,16 Both THC and CBD have been demonstrated to bind and', 'modulate various receptors within the ECS to mediate their proposed therapeutic effects.', 'Despite accumulating experimental and clinical evidence both for and against the use of cannabis products', 'in subjects with chronic pain, there are limited guidelines or standards of care to facilitate the safe and', 'effective prescription of cannabinoid formulations by physicians who treat subjects with chronic pain. This', 'study aims to establish a Spectrum Therapeutics (ST) Chronic Pain Registry that will collect descriptive,', 'clinical, and outcome data on the use of ST medical cannabis products in subjects with chronic pain. These', 'real-world data will provide insights regarding physician-recommended treatment regimens, titration,', 'safety, and changes in self-reported pain relief, daily function, and quality of life. Additionally, data', 'generated from the registry will aid in the development of further controlled clinical studies, market access', 'initiatives, educational programs, and future publications.', '1.2', 'Rationale', 'Primary chronic pain and chronic musculoskeletal pain are the most common reasons people cite for using', 'medical cannabis products 13,17-20 Rapid changes in the global regulatory landscape regarding medical use', 'of cannabis and cannabinoids have had a significant impact on health care professionals who currently', 'receive little or no education on medical cannabis19 Appropriate knowledge about the use of medical', 'cannabis and evidence to support the development of clinical guidelines is essential for the effective use of', 'medical cannabis by health care professionals. This sentiment parallels requests for the development of', 'research in this area by professionals and the media 20,21', '25 November 2020', 'CONFIDENTIAL', 'Page 14 of 79']\n\n###\n\n", "completion": "END"}